[go: up one dir, main page]

BR112014027231A2 - comprimido contendo 5-hidróxi-1h-imidazola-4-carboxamida - Google Patents

comprimido contendo 5-hidróxi-1h-imidazola-4-carboxamida

Info

Publication number
BR112014027231A2
BR112014027231A2 BR112014027231A BR112014027231A BR112014027231A2 BR 112014027231 A2 BR112014027231 A2 BR 112014027231A2 BR 112014027231 A BR112014027231 A BR 112014027231A BR 112014027231 A BR112014027231 A BR 112014027231A BR 112014027231 A2 BR112014027231 A2 BR 112014027231A2
Authority
BR
Brazil
Prior art keywords
carboxamide
imidazole
hydroxy
tablet containing
tablet
Prior art date
Application number
BR112014027231A
Other languages
English (en)
Inventor
Yamasaki Yasuomi
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of BR112014027231A2 publication Critical patent/BR112014027231A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “comprimido contendo 5-hidróxi-1h-imidazola-4-carboxamida” trata-se de um comprimido contendo (1) 5-hidróxi-1h-imidazola-4-carboxamida, um sal, ou um hidrato da mesma, e (2) dióxido de silício, em que o teor de 5-hidróxi-1h-imidazola-4-carboxamida, sal, ou hidrato da mesma é alto. o comprimido tem um tamanho que torna fácil a ação de tomar o mesmo, e é excelente em termos de capacidade de liberação.
BR112014027231A 2013-01-15 2014-01-15 comprimido contendo 5-hidróxi-1h-imidazola-4-carboxamida BR112014027231A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013004995 2013-01-15
PCT/JP2014/050591 WO2014112530A1 (ja) 2013-01-15 2014-01-15 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミドを含有する錠剤

Publications (1)

Publication Number Publication Date
BR112014027231A2 true BR112014027231A2 (pt) 2017-06-27

Family

ID=51209619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027231A BR112014027231A2 (pt) 2013-01-15 2014-01-15 comprimido contendo 5-hidróxi-1h-imidazola-4-carboxamida

Country Status (17)

Country Link
US (1) US9248102B2 (pt)
EP (1) EP2946780B1 (pt)
JP (1) JP5805891B2 (pt)
CN (1) CN104271134B (pt)
BR (1) BR112014027231A2 (pt)
CY (1) CY1119159T1 (pt)
DK (1) DK2946780T3 (pt)
ES (1) ES2622568T3 (pt)
HR (1) HRP20170571T1 (pt)
LT (1) LT2946780T (pt)
PL (1) PL2946780T3 (pt)
PT (1) PT2946780T (pt)
RS (1) RS56032B1 (pt)
RU (1) RU2654703C2 (pt)
SI (1) SI2946780T1 (pt)
SM (1) SMT201700220T1 (pt)
WO (1) WO2014112530A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2018051971A1 (ja) * 2016-09-13 2018-03-22 富士フイルム株式会社 Ｍｌｌ関連白血病の予防または治療のための医薬、方法、使用及び化合物
WO2019082898A1 (ja) 2017-10-27 2019-05-02 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の製造方法
RU2018134165A (ru) * 2018-09-03 2020-04-01 Фуджифилм Корпорэйшн Комбинированное фармацевтическое, профилактическое или супрессивное средство для подавления резистентности к пиримидиновому антиметаболиту и способ лечения заболевания

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS604802B2 (ja) 1976-09-07 1985-02-06 住友化学工業株式会社 制癌剤
US4181731A (en) * 1976-09-07 1980-01-01 Sumitomo Chemical Company, Limited Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
JPS5824569A (ja) 1981-08-05 1983-02-14 Sumitomo Chem Co Ltd イミダゾ−ル誘導体の精製方法
JPS60185727A (ja) 1984-03-05 1985-09-21 Sumitomo Chem Co Ltd ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法
JPH048468A (ja) * 1990-04-27 1992-01-13 Sanshin:Kk ワーク研摩機
JPH09208468A (ja) * 1996-02-02 1997-08-12 Dainippon Pharmaceut Co Ltd ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
JP5021210B2 (ja) * 2006-01-16 2012-09-05 エスエス製薬株式会社 圧縮成型製剤
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5266010B2 (ja) 2007-09-14 2013-08-21 富士フイルム株式会社 ４−カルバモイル−５−ヒドロキシ−イミダゾール誘導体のスルホン酸塩化合物
PT2407166E (pt) * 2009-03-13 2013-11-25 Toyama Chemical Co Ltd Comprimido e pó granulado que contêm 6-fluoro-3-hidroxi-2-pirazinacarboxamida

Also Published As

Publication number Publication date
JP5805891B2 (ja) 2015-11-10
EP2946780B1 (en) 2017-03-01
PL2946780T3 (pl) 2017-07-31
JPWO2014112530A1 (ja) 2017-01-19
DK2946780T3 (en) 2017-05-08
WO2014112530A1 (ja) 2014-07-24
CY1119159T1 (el) 2018-02-14
RU2654703C2 (ru) 2018-05-22
RS56032B1 (sr) 2017-09-29
CN104271134B (zh) 2016-06-29
SI2946780T1 (sl) 2017-05-31
US20150057324A1 (en) 2015-02-26
US9248102B2 (en) 2016-02-02
LT2946780T (lt) 2017-06-12
SMT201700220T1 (it) 2017-07-18
CN104271134A (zh) 2015-01-07
HRP20170571T1 (hr) 2017-08-11
EP2946780A1 (en) 2015-11-25
ES2622568T3 (es) 2017-07-06
RU2014143976A (ru) 2016-05-27
HK1205463A1 (zh) 2015-12-18
PT2946780T (pt) 2017-04-26
EP2946780A4 (en) 2016-06-08

Similar Documents

Publication Publication Date Title
TWD182032S (zh) 行李箱（六）
EP2948764A4 (en) WATER TREATMENT SYSTEMS, DEVICES AND METHOD FOR LIQUID PREPARATION
BR112015029848A8 (pt) dispositivos de recepção e de transmissão, métodos para recepção de um dispositivo de recepção e para transmissão de um dispositivo de transmissão, e, meio de armazenamento legível por computador
BR112016009874A2 (pt) Dispositivos de liberação de fármaco, e composições farmacêuticas e usos
EP3060129A4 (en) DEVICES, SYSTEMS AND METHOD FOR VESSEL TESTING
BR112015028319A2 (pt) copolímero de propileno para embalagem com pequena espessura
BR112017001315A2 (pt) fundamentos do dispositivo de computação modular
BR112014008905A2 (pt) método implementado por um ou mais dispositivos computacionais e dispositivo computacional
BR112015020584A2 (pt) métodos para o tratamento de artrite psoriática usando apremilast
BR112017003270A2 (pt) inércia paramétrica e apis
TWD167038S (zh) 瓶子
BR112017002947A2 (pt) conceito para comutação de taxas de amostragem em dispositivos de processamento de áudio
CR20160136A (es) Compuestos heterocíclicos
GB2524448B (en) Identifying workload and sizing of buffers for the purpose of volume replication
EA201690036A1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
BR112014027231A2 (pt) comprimido contendo 5-hidróxi-1h-imidazola-4-carboxamida
PT2948160T (pt) Composições que contêm sulfato de condroitina, nattokinase e compostos de sulfidrilo para melhorar a biodisponibilidade de sulfato de condroitina
BR112015028133A2 (pt) canal de operações especiais em sistemas vetorizados
GB201311727D0 (en) Controlling access to one or more datasets of an operating system in use
BR112015016994A2 (pt) uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para o tratamento, melhoria, prevenção ou atraso no progresso da narcolepsia, sonolência diurna excessiva, disrupção do sono noturno e/ou cataplexia
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
BR112016000468A2 (pt) método, um ou mais meios de armazenamento não transitórios legíveis por computador e dispositivo
AR098670A1 (es) Inhibidor de sglt1
TWD159611S (zh) 酒瓶
MX362686B (es) Inmunógenos fúngicos y materiales y métodos relacionados.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements